为解决弥漫大 B 细胞淋巴瘤（DLBCL）患者治疗中面临的耐药和复发问题，研究人员开展了 DLBCL 与血管生成相关基因（ARGs）的研究。他们构建了基于 7 个 ARGs 的预后模型，发现该模型与临床特征及免疫微环境相关。这为改善 DLBCL 诊疗提供了理论依据。

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

诺诚健华（香港联交所代码：09969；上交所代码：688428）今天宣布，公司将在2025年美国临床肿瘤学会（ASCO）年会上公布一系列创新管线最新数据。

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Apr. 4, 2025 — A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...

In an inspiring twist of fate, beloved actor Dave Coulier is sharing his triumphant health journey after battling stage 3 non ...